Now Playing
|Videos|March 24, 2023
Basal Cell Carcinoma Management Challenges
Author(s)John Strasswimmer, MD, PhD
John Strasswimmer MD, PhD provides a recap of a panel discussion from Winter Clinical in Miami, Florida highlighting the management challenges providers face in patients with locally advanced basal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Menopause and the Skin: Recognizing Changes Beyond Aging
3
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
4
Social Media Mythbusters: Can Face Taping Really Prevent Wrinkles?
5